Endocrine abnormalities in chronic renal failure

被引:39
作者
Leavey, SF [1 ]
Weitzel, WF [1 ]
机构
[1] Univ Michigan, Hlth Syst, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0889-8529(01)00006-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Much needs to be achieved for improving the survival and quality of life for chronic renal failure patients. Progress in attaining this goal may accrue from attention to underlying pathophysiologic processes early on and throughout a person's life history of chronic renal failure. The endocrine perturbations described in this review are alterations in the homeostasis of phosphorus, calcium, vitamin D, and parathyroid hormone; erythropoietin deficiency; and sexual dysfunction in uremia-good examples for the need to identify early and manage prospectively over time manifestations of chronic renal failure. The complexity of both the skeletal and extra-skeletal sequelae of dysregulated mineral metabolism and the complications of chronic anemia are discussed while stressing possible implications of these endocrine abnormalities for both morbidity and mortality. There is a great need for more randomized clinical trials to evaluate new and old treatment approaches, with the goal of developing better evidence-based practice guidelines.
引用
收藏
页码:107 / +
页数:14
相关论文
共 42 条
[1]  
[Anonymous], 1997, Am J Kidney Dis, V30, pS192
[2]  
[Anonymous], USRDS 1999 ANN DAT R
[3]   A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure -: Rapid communication [J].
Antonsen, JE ;
Sherrard, DJ ;
Andress, DL .
KIDNEY INTERNATIONAL, 1998, 53 (01) :223-227
[4]   1,25(OH)2D3 ADMINISTRATION IN MODERATE RENAL-FAILURE - A PROSPECTIVE DOUBLE-BLIND TRIAL [J].
BAKER, LRI ;
ABRAMS, SML ;
ROE, CJ ;
FAUGERE, MC ;
FANTI, P ;
SUBAYTI, Y ;
MALLUCHE, HH .
KIDNEY INTERNATIONAL, 1989, 35 (02) :661-669
[5]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[6]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[7]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[8]  
BRICKER NS, 1972, NEW ENGL J MED, V286, P1093
[9]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[10]   Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Dillon, MA ;
Slatopolsky, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2907-2914